AGM 2018 - European Society of Gene and Cell Therapy (ESGCT)
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
AGM 2018
Date and time: 19 October 2018, 17:00
Location: SwissTech Convention Center, Lausanne, Switzerland
Chair: Robin Ali (RA) (ESGCT president)
Opening
RA opens the meeting and presents agenda.
Elections
RA presents the results of the Board election.
Lausanne 2018
RA presents the statistics for the 2018 Annual Congress. 1303 delegates registered,
which is a record for the society. For the first time, there are more registrations from
industry than academia. RA summarises that the 2018 Annual Congress was a very
successful meeting and refers to the excellent location, venue, food and the strong
and varied programme.
Awards
RA presents the winners of the Travel Grants and OAA and YIA. Didier Trono (OAA)
delivered his award lecture on Tuesday, Alessio Cantore (YIA) will speak later today.
Membership
RA presents membership statistics. ESGCT currently has 1003 members, for the first
time >1000. Over the past few years, there has been a dramatic rise in membership
overall, but particularly in industry memberships.
2017 accounts
RA presents the financial situation of the society. The positive current bank balance
means that the society is financially secure and can also invest in new activities and
grants. The society can invest further in, for example, travel grants and the Spring
School which already benefit PhD students and ECRs.
Initiatives
RA says that ESGCT’s main aims are to promote science, exchange knowledge,
educate the next generation of graduate students, engage general public and work
with regulatory agencies. He then presents impact initiatives that ESGCT is planning
for the future.
Partnerships
RA presents partnerships with national societies of gene and cell therapy, international
societies including ISSCR, ASGCT and JSGCT, and the society journal HGT.
Next AGM
RA announces that the next AGM will take place on Friday 25 October 2019 in
Barcelona, Spain during the 2019 Annual Congress.
Close
RA asks whether there are any questions and, in the absence of any questions, closes
the AGM.
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
AGM SLIDES
Annual General Meeting
of the
European Society of
Gene & Cell Therapy
19th October 2018
SwissTech Convention Centre
(Lausanne, SWITZERLAND)
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
Agenda
1. ESGCT Board: nominations and elections
2. Lausanne 2018: first impressions
3. Financials: 2017 accounts
4. ESGCT: Impact projects
5. Future events
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
Agenda
1. ESGCT Board: nominations and elections
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
Elections
RESULTS: elected members to the Board
Alessandro Aiuti
Giuliana Ferrari
Gloria Gonzalez Aseguinolaza
Zoltan Ivics
Axel Schambach
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
Agenda
2. Lausanne 2018: first impressions
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
Registration stats
Total registrations:
1302 registrations Academic Student Industry
1303 513 152 598
of which members 354 (69%) 100% 211 (35%)
565 abstracts INV OR POS
90 31 444
**Onsite registrations 16-18 October: 37, bringing total to 1302 final registrations
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
Travel Grant winners
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
Programme Highlights
Award winners
Agenda
3. Financials: 2017 accounts
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
Membership
2013 2014 2017 2018
2015 2016
Madrid The Hague Berlin Lausanne
Helsinki Florence
with with with with ISSCR
with FSGT with ISSCR
SETGYC NVGCT DGGT & SFTCG
TOTAL 462 422 528 961 977 1003
Academic 42% 43% 30% 55% 35% 45%
194 181 158 529 342 452
Students 45% 45% 49% 20% 40% 28%
208 190 259 192 391 280
Industry 13% 12% 21% 25% 25% 27%
60 51 111 240 244 271
2017 accounts
Cash in bank 2016
€360,000
Revenue from Annual Congress 2017 (Berlin, Germany)
€90,000
Income membership 2017
€72,000
ESGCT Spring School
(€34,000)
Accounting and tax reporting
(€7,400)
Cashflow retainer for prepayments* and loss assurance €400,000
Cash in bank for 2018 investment in Impact projects €80,000
*Prepayments: venue and other deposits and outgoings (insurance) Annual
Congress 2019, 2020, and Spring School 2019, 2020
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
2017 investment:
Students and ECR
- Subsidised congress fee - students €97,650
- Free student membership
€11,700
- Travel grants
€3,000
- Full subsidy of Spring School
€34,000
Total investment in students and ECR €146,350
Agenda
4. ESGCT: Impact initiatives 2019 and beyond
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
ESGCT priorities & goals
1. PROMOTE science and research in gene and cell
therapy
2. EDUCATE through engagement activities
3. EXCHANGE of information & ideas
4. ENCOURAGE research & clinical application
5. COLLABORATE with other societies, organisations,
and institutions
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
ESGCT Impact Initiatives
Students and Early Career Researchers Stakeholders and Society
● Spring School ● Regulatory Roundtables
● Inter-lab bursary scheme ● Activity Heatmap of Europe
● Travel Grants ● Printable education packs for
● Masterclasses - in person and schools
online: presentation skills, ● Blog and online forum
abstract writing etc.
Supporting future leaders
A voice for gene and cell therapy in Europe
Supporting and promoting diversity
Sharing expertise and resources
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UK
AGM 2018
ESGCT Partnerships
ü Supporting national societies: meeting funding support,
extending reach into national communities
ü International collaborations: ISSCR, ASGCT, JSGCT
ü Human Gene Therapy:
- special rates for members
- supporting European research
- many ESGCT members are part of the editorial Board
- opportunities for contributions from students and
established researchers e.g. Vanessa Woods & Mark Brimble
NEXT
Annual General Meeting
of the
European Society of
Gene & Cell Therapy
Friday 25th October 2019
CCIB Convention Centre
(Barcelona, SPAIN)
ESGCT / ISSCR / SFTCG Collaborative Congress Lausanne (Switzerland) 2018
ESGCT Board Registered address
Robin Ali, UK (President) European Society for Gene and Cell Therapy W www.esgct.eu
Hildegard Büning, Germany (Vice-President) c/o Prof. Christof von Kalle
Christof von Kalle, Germany (Treasurer) T +44 7787 047 977
Deutsches Krebsforschungszentrum (DKFZ)
Juan Bueren, Spain, (General Secretary) Abteilung Translationale Onkologie E office@esgct.eu
Nathalie Cartier-Lacave, France G100 Im Neuenheimer Feld 460
Alessandro Aiuti, Italy 69120 Heidelberg ESGCT Office
Alberto Auricchio, Italy Germany 1 Abbey Street
Vincenzo Cerullo, Finland Eynsham, Oxfordshire
Zoltan Ivics, Germany VAT: DE 304446032 OX29 4TB United Kingdom
Adrian Thrasher, UKYou can also read
